A Phase IIB, 28-Day, Randomized, Double-Blind Placebo-Controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Trial Profile

A Phase IIB, 28-Day, Randomized, Double-Blind Placebo-Controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2017

At a glance

  • Drugs Revefenacin (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Theravance; Theravance Biopharma
  • Most Recent Events

    • 20 May 2015 According to Theravance Biopharma media release, results presented at the American Thoracic Society (ATS) 2015 International Conference.
    • 20 May 2015 Results published in the Theravance Biopharma media release.
    • 10 Mar 2015 In Dec 2014, following the announcement of positive top-line results of the phase IIb program, Theravance Biopharma conducted an end-of-phase II meeting with the FDA to discuss the design of the phase III registrational program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top